AstraZeneca PLC (AZN)
NYSE: AZN · Real-Time Price · USD
168.37
+0.27 (0.16%)
At close: Sep 22, 2026, 4:00 PM EDT
168.45
+0.08 (0.05%)
After-hours: Sep 22, 2026, 7:47 PM EDT
AstraZeneca Market Cap
AstraZeneca has a market cap or net worth of $262.23 billion as of September 22, 2026. Its market cap has increased by 10.89% in one year.
Market Cap
262.23B
Enterprise Value
289.84B
1-Year Change
10.89%
Ranking
Category
Stock Price
$168.37
ChartMarket Cap Chart
Since November 21, 2000, AstraZeneca's market cap has increased from $126.35B to $262.23B, an increase of 107.53%. That is a compound annual growth rate of 2.86%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 22, 2026 | 262.23B | -7.99% |
| Dec 31, 2025 | 284.98B | 40.31% |
| Dec 31, 2024 | 203.11B | -2.65% |
| Dec 29, 2023 | 208.65B | -0.60% |
| Dec 30, 2022 | 209.91B | 20.44% |
| Dec 31, 2021 | 174.28B | 32.86% |
| Dec 31, 2020 | 131.17B | 1.42% |
| Dec 31, 2019 | 129.34B | 34.47% |
| Dec 31, 2018 | 96.18B | 9.54% |
| Dec 29, 2017 | 87.81B | 27.12% |
| Dec 30, 2016 | 69.07B | -19.47% |
| Dec 31, 2015 | 85.77B | -3.07% |
| Dec 31, 2014 | 88.48B | 19.53% |
| Dec 31, 2013 | 74.02B | 21.17% |
| Dec 31, 2012 | 61.09B | -6.34% |
| Dec 30, 2011 | 65.22B | -2.68% |
| Dec 31, 2010 | 67.02B | -1.37% |
| Dec 31, 2009 | 67.95B | 13.67% |
| Dec 31, 2008 | 59.78B | -7.97% |
| Dec 31, 2007 | 64.96B | -23.07% |
| Dec 29, 2006 | 84.44B | 6.23% |
| Dec 30, 2005 | 79.49B | 29.74% |
| Dec 31, 2004 | 61.26B | -26.15% |
| Dec 31, 2003 | 82.95B | 37.87% |
| Dec 31, 2002 | 60.17B | -55.10% |
View and export this data all the way back to 2000. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Johnson & Johnson | 650.65B |
| AbbVie | 466.45B |
| Merck & Co. | 362.35B |
| Novartis AG | 265.70B |
| Amgen | 208.49B |
| Novo Nordisk | 191.02B |
| Gilead Sciences | 186.13B |
| Pfizer | 157.65B |